On August 11, 2025, SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced it has raised $140 million in private financing, including $25 million in the second tranche of its Series C financing and $115 million in Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group. Wilson Sonsini Goodrich & Rosati advised SetPoint Medical on the transaction.

Proceeds of the financing will support commercialization of the SetPoint System, a first-of-its-kind neuroimmune modulation therapy for adults living with moderate-to-severe rheumatoid arthritis (RA), and advancement of the company’s pipeline in other autoimmune conditions.

The Wilson Sonsini team that advised SetPoint Medical on the transaction includes Philip Oettinger, RJ Lang, Kevin Roesser, and Jackie Ito.

For more information, please see SetPoint Medical’s news release.